Isracann Biosciences Inc. (OTCMKTS:ISCNF) Short Interest Down 96.5% in January
Isracann Biosciences Provides Bi-Weekly Default Status Report
Isracann Biosciences Announces Delay in Filing Annual Financial Statements
Isracann Bioscience Facilitated Genetics Arrive in Israel
Isracann Bioscience Facilitates Cannabis Genetics Shipment to Israel
Isracann's Praesidio Expands Its Natural Health Products Distribution Network: Inks Deal With Pure Integrative Pharmacy
Praesidio Signs Distribution Agreement With Pure Integrative Pharmacy
US Cannabis Council & Other Marijuana Players Just Made Some Key Executive Changes You Should Know About
Isracann Adds Super Bowl MVP and Mental Health Advocate Mark Rypien to Advisory Board
Cannabis Company Isracann Biosciences Raises $234K In The First Tranche Of Private Placement
Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement
Isracann Biosciences' Subsidiary Praesidio Health Submits NPNs To Health Canada
Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada
Isracann Biosciences Inc. (OTCMKTS:ISCNF) Sees Significant Decrease in Short Interest
Isracann Biosciences Signs Definitive Agreement To Acquire Praesidio Health For $3.18M
Isracann Biosciences to acquire Canadian natural health medicine developer
Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer
UPDATE - Isracann Signs LOI to Acquire Natural Health Medicine Developer
Isracann To Acquire Natural Health Medicine Developer Praesidio Health For $3.14M
Isracann to acquire natural health medicine developer
No Data
No Data